FDA Pulls Lymphoma Approvals for PI3K Inhibitor Umbralisib Worse overall survival observed despite improvements in progression-free survival Jun 01, 2022
Allo-Transplant With Omidubicel Hints at Longer-Term Benefits Too "Viable" option for patients eligible for umbilical cord blood transplantation, investigator says Apr 27, 2022
Promising Data for Allo-Transplant After CAR T-Cell Failure in LBCL Durable responses with no unexpected or prolonged safety issues Apr 27, 2022
Bispecific Antibody-NK Cell Complex Impresses in Early Hodgkin/NHL Trial Objective responses in 89% of patients with no CRS, neurotoxicity, or graft-versus-host disease Apr 11, 2022
9/11 Responders More Likely to Carry Genetic Mutations Tied to Cancer Clonal hematopoiesis seen in 10% of firefighters, medical personnel on the scene after WTC attack Mar 07, 2022
FDA Concerned About Safety of Lymphoma Drug Hint of excess mortality in trial of umbralisib/ublituximab prompts public notice Feb 03, 2022
Growing Controversy Over 'Skinny' Labeling for Generic Drugs What's at stake in legal battles over patent-avoiding approval pathway for generics Jan 17, 2022
Less Is More: Rituximab Retreatment Tops Maintenance for Follicular Lymphoma Updated analysis confirms advantages of less aggressive approach to low-burden disease Dec 16, 2021
CAR T-Cell Win Streak Stopped by Negative Trial in Aggressive LBCL Patients, trial design, logistics among possible explanations for lack of EFS benefit Dec 14, 2021
R-CHOP Toppled in First-Line DLBCL Trial Replacing vincristine with polatuzumab vedotin improved PFS, without adding toxicity Dec 14, 2021
R2 Maintenance for Elderly MCL Patients Worth the Risk? Longer PFS with addition of lenalidomide to rituximab, but also more toxicity Dec 13, 2021
Novel Bispecific Antibody Nets Durable Remissions in Follicular Lymphoma Mosunetuzumab offers "clinically meaningful outcomes" in relapsed/refractory disease Dec 12, 2021
CAR T-Cell Therapy Makes Strong Case for Earlier Use in Lymphoma Large increases in event-free survival with two CAR T-cell products in second line Dec 11, 2021
Chemo-Free Regimen Highly Active in Older Mantle Cell Lymphoma Patients Overall response rate of 96% with ibrutinib-rituximab, but cardiotoxicity a possible issue Nov 29, 2021
Novel Triplet Yields Undetectable MRD Status in 90% of CLL/SLL Patients Zanubrutinib plus obinutuzumab and venetoclax was also well tolerated Nov 29, 2021
Ceritinib Shows Promise in ALK-Positive Pediatric Malignancies Responses seen in neuroblastoma, among other tumors Nov 17, 2021
Ibrutinib Boosts Survival in Younger Patients With Certain DLBCL Subtypes New analysis "casts the PHOENIX trial in a new light," authors say Nov 04, 2021
Ibrutinib-Rituximab Wins Out in Waldenstrom's Macroglobulinemia Risk of disease progression or death reduced by 75% versus rituximab alone Oct 11, 2021
9/11 Responders Face Higher Risk of Multiple Cancers Longer follow-up sheds light on the long-term consequences of exposure to disaster site Sep 10, 2021
Lymphoma in RA: Disease Activity Matters Strongest risk factors were baseline disease activity scores and bone erosions Sep 08, 2021
Non-Chemo Regimen Highly Active in R/R Hodgkin Lymphoma Three-year progression-free survival of 77%, including 91% after stem-cell transplantation Aug 23, 2021
How CAR T-Cell Therapy Measures Up in Follicular Lymphoma Better response rates and survival with axicabtagene ciloleucel versus external control group Jun 15, 2021
COVID Vaccine Protection; 'Until You Die From the Cancer'; What's Palliative Care? News, features, and commentary about cancer-related issues Jun 10, 2021
Another CAR-T Impresses in Follicular Lymphoma Complete responses in 66% of patients with relapsed or refractory disease Jun 08, 2021
Thiotepa-Based Conditioning Promising for Primary CNS Lymphoma Commonly used regimens with autologous transplant improved survival May 06, 2021
Add-On PI3K Inhibitor Wins in Relapsed, Indolent NHL Adding copanlisib to rituximab also doubled CR rate, with manageable toxicity Apr 10, 2021
Op-Ed: Blood Cancer Patients Need More COVID Vax Answers Patients are left wondering, "will I be protected?" Mar 24, 2021
Anti-CD20 Drugs Tied to Severe COVID in Cancer Patients Plus: Active chemo treatment may not be a COVID risk factor Feb 05, 2021
JAK Inhibitor Misses Endpoint in Safety Study. Now What? Major blow to popular class of oral rheumatology drugs Jan 27, 2021
Non-Hodgkin Lymphoma: Bispecific Antibodies Impress in Refractory Disease Odronextamab, epcoritamab surpass 90% response threshold in early trials Dec 11, 2020
Blood Cancers and COVID-19: 'A Medically Vulnerable' Group Patients with hematologic malignancies and SARS-CoV-2 face higher risks for infection, death Dec 06, 2020
HIV: Don't Quit on Hope, Says 'London Patient' IAC roundtable addresses prospects for cure, now proven to be possible Jul 06, 2020
Minimal Link Between Eczema and Most Cancers Study finds severe eczema tied to small risk for lymphoma Jun 30, 2020
Cancer Immunotherapy Tied to Severe COVID-19 Outcomes Nearly threefold increased risk of hospitalization, severe respiratory illness Jun 25, 2020
Worse Blood Cancer Outcomes in Hispanics Diagnosis at earlier age, worse survival, especially for those on U.S.-Mexico border Jun 24, 2020
Keytruda Tops Adcetris in Head-to-Head Hodgkin's Trial Checkpoint inhibitor improved PFS in refractory and transplant-ineligible cases Jun 15, 2020
CAR T-Cell Therapy Impresses in Indolent NHL Overall response rate exceeding 90% with axi-cel in relapsed/refractory setting May 31, 2020
Nivolumab-Based Tx Effective in Early, Unfavorable Hodgkin's Interim results showed high CR rates and almost 100% PFS, OS at 12 months May 01, 2020
COVID-19 Mortality Spikes in Patients With Lung, Blood Cancers Those with metastatic disease also at special risk for poor outcomes Apr 28, 2020
DOAC Works in Cancer-Related VTE, No Tradeoff in Bleeds Apixaban monotherapy matches dalteparin in non-inferiority trial Mar 29, 2020
